You may be eligible for the Mission AD study if you:
Are age 50 to 85
Have noticeable changes in your memory and thinking abilities that might be related to Mild Cognitive Impairment (MCI) or mild dementia due to early Alzheimer's disease (AD)
Have a study partner who knows you well and can attend certain visits with you and tell us about your health and well-being
About the Study:
Do you feel your memory isn't what it used to be? Do you or a loved one have a diagnosis of Mild Cognitive Impairment (MCI) or dementia due to the early stages of Alzheimer's disease (AD)? Are you between the ages of 50 to 85?
Please consider participating in a clinical trial of a new treatment to help people with Mild Cognitive Impairment (MCI) or dementia due to the early stages of Alzheimer's disease (AD).
The Mission AD study is assessing the effectiveness and safety of an investigational medication (a "BACE inhibitor" that stops the formation of the building blocks of amyloid in the brain) to improve the symptoms of Alzheimer's disease. The sponsor of this study is Eisai pharmaceutical company.
This international trial will enroll 1,330 volunteers
This trial will last for approximately 29 months, followed by a 24-month open-label optional extension study.
Most visits for this trial will be conducted at the Center for Alzheimer Research and Treatment at Brigham & Women's Hospital, but a few visits will be conducted at Massachusetts General Hospital
Additional optional substudies are available
At the beginning of the trial, we ask study participants to make more frequent visits to ensure satisfaction and safet
There is no cost associated with participating in this trial
What is Involved:
Study activities may include memory and thinking tests, possible lumbar punctures (spinal taps), as well as the activities listed below: